Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Leber

Showing results (81-90 of 125) with videos related to

Pageof 13
Sort By:
Blood Advances|August 11, 2018
A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemiaLili Aslostovar, Allison L Boyd, Mohammed Almakadi, et al.
Leukemia Research|December 18, 2019
The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemiaChristopher M Hillis, Nicholas L Jackson Chornenki, Isabelle Bence-Bruckler, et al.
Cell Reports. Medicine|March 5, 2021
Abnormal dopamine receptor signaling allows selective therapeutic targeting of neoplastic progenitors in AML patientsLili Aslostovar, Allison L Boyd, Yannick D Benoit, et al.
Cancer|April 15, 2025
Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemiaBrian Leber, Marcia T Ruiz, Hany Elgendy, et al.
Cell Reports|March 17, 2021
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patientsJennifer C Reid, Diana Golubeva, Allison L Boyd, et al.
Leukemia & Lymphoma|July 31, 2019
Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are availableLynda Foltz, Gian-Matteo Pica, Hacene Zerazhi, et al.
Journal of Hematology & Oncology|July 16, 2020
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapyJorge E Cortes, Florian H Heidel, Walter Fiedler, et al.
JCO Oncology Practice|February 10, 2023
Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic SyndromesLee Mozessohn, Qing Li, Ning Liu, et al.
Transfusion|February 7, 2024
Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC-ENHANCERena Buckstein, Jeannie Callum, Anca Prica, et al.
Leukemia Research|September 1, 2023
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapyFatima M Khadadah, Sonia Cerquozzi, Harold J Olney, et al.
Pageof 13

Showing results (81-90 of 125) with videos related to

Sort By:
Pageof 13
Blood Advances|August 11, 2018
A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemiaLili Aslostovar, Allison L Boyd, Mohammed Almakadi, et al.
Leukemia Research|December 18, 2019
The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemiaChristopher M Hillis, Nicholas L Jackson Chornenki, Isabelle Bence-Bruckler, et al.
Cell Reports. Medicine|March 5, 2021
Abnormal dopamine receptor signaling allows selective therapeutic targeting of neoplastic progenitors in AML patientsLili Aslostovar, Allison L Boyd, Yannick D Benoit, et al.
Cancer|April 15, 2025
Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemiaBrian Leber, Marcia T Ruiz, Hany Elgendy, et al.
Cell Reports|March 17, 2021
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patientsJennifer C Reid, Diana Golubeva, Allison L Boyd, et al.
Leukemia & Lymphoma|July 31, 2019
Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are availableLynda Foltz, Gian-Matteo Pica, Hacene Zerazhi, et al.
Journal of Hematology & Oncology|July 16, 2020
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapyJorge E Cortes, Florian H Heidel, Walter Fiedler, et al.
JCO Oncology Practice|February 10, 2023
Impact of Frailty on Health Care Resource Utilization and Costs of Care in Myelodysplastic SyndromesLee Mozessohn, Qing Li, Ning Liu, et al.
Transfusion|February 7, 2024
Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC-ENHANCERena Buckstein, Jeannie Callum, Anca Prica, et al.
Leukemia Research|September 1, 2023
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapyFatima M Khadadah, Sonia Cerquozzi, Harold J Olney, et al.
Pageof 13